Solana Beach resident Nora Aust celebrated her 100th birthday in March with a short parade route along her neighborhood and a party with her children, neighbors, family and friends.
GlaxoSmithKline poached Pfizer's RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it's lost many research staffers this past year. Parthenon Therapeutics snagged Johnson & Johnson's global head of cell therapy platform and discovery, Tamas Oravecz, Ph.D. And Rafael parted ways with five execs and reinstalled telecom tycoon Howard Jonas as CEO.
— Tomo, a new real estate startup led by ex-Zillow leaders, announced Sarah Makar as CMO. She is also a Zillow alum and was most previously SVP of marketing at…
Seattle, Washington (PRWEB) November 30, 2021 A-Alpha Bio, a biotechnology company improving human health by unlocking the potential of protein-protein
Finding the best ways to do good.
The Covid-19 pandemic is still a threat. The virus is currently walloping India, Brazil, and other countries, and new waves could yet erupt in places where the pandemic had been suppressed.
But the devastation of the past year has come with one big silver lining: a massive leap forward in vaccine development.
The Pfizer/BioNTech, Moderna, Johnson & Johnson, and AstraZeneca/Oxford vaccines were made possible by recent innovations in vaccine platform technology. Vaccines, which generally required the use of dead or inactive viruses, used to take years to develop. The new generation of mRNA vaccines (in the case of Pfizer and Moderna) and adenovirus vaccines (in the case of Johnson & Johnson and AstraZeneca) has simplified the process of developing vaccines for new diseases.